Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cognizin Can Reduce Cocaine Use

Study: lessens dependence in bipolar patients

Publish date:: July 16, 2015

Cocaine use among patients with bipolar 1 disorder and cocaine dependence was reduced with Cognizin (citicoline) when compared with placebo in study of 130 outpatients. The 12-week study, which was based on urine drug screens, also suggested:

• Cognizin citicoline could be used as part of an augmentation strategy for the treatment of cocaine dependence in bipolar patients.

• Cognizin citicoline decreased cocaine use without impacting mood.

• The citicoline group saw no significant group differences in manic or depressive symptoms following supplementation.

Citation: Brown ES, Peterson Todd J, Hu LT, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry. [Published online before print May 22, 2015]. doi: 10.1176/appi.ajp.2015.14070857.

This Week's Must Reads

MDD: Modest improvements in female sexual functioning with adjunctive brexpiprazole,

Transcranial direct current stimulation not clinically relevant in MDD,

Interleukin-1 β and TNF-α hamper antidepressant response in MDD,

Impact of pimavanserin on anxious depression in patients with MDD,

Prior MDD moderates the association between endothelin-1 and post-ACS depressive symptoms,

Must Reads in Addiction Medicine

E-cigarette use tied to increased COPD, asthma risk,

National lung cancer screening guidelines may miss younger African American individuals at high risk,

Alcohol problems linked to legal performance-enhancement products,

Report describes intoxication with new psychoactive substance,

Adolescent alcohol, opioid misuse linked to risky behaviors,